XOPENEX HFA
SABA MDI
Levalbuterol tartrate · Sunovion Pharmaceuticals
Active Medication & Mechanism
- Levalbuterol tartrate SABA45 mcg levalbuterol per actuation
R-enantiomer of racemic albuterol. Short-acting beta2-adrenergic agonist. Selectively stimulates beta2-receptors on airway smooth muscle, producing rapid bronchodilation. May have fewer beta1-mediated cardiac side effects than racemic albuterol.
FDA-Approved Dosing by Indication
// approval varies by strength + age Asthma
1/1 approved regimens| Strength | Population | Dose & Frequency | Total Daily | Status |
|---|---|---|---|---|
| 45 mcg | Patients ≥4 years | 2 inhalations (90 mcg) every 4–6 hours as needed Treatment or prevention of bronchospasm in patients ≥4 years with reversible obstructive airway disease. | As needed; 1 inhalation (45 mcg) may suffice in some patients | FDA Approved |
Exercise-Induced Bronchospasm
1/1 approved regimens| Strength | Population | Dose & Frequency | Total Daily | Status |
|---|---|---|---|---|
| 45 mcg | Patients ≥4 years | 2 inhalations 15–30 minutes before exercise Prevention of exercise-induced bronchospasm. | As needed | FDA Approved |